ATE541053T1 - Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs - Google Patents

Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs

Info

Publication number
ATE541053T1
ATE541053T1 AT06022167T AT06022167T ATE541053T1 AT E541053 T1 ATE541053 T1 AT E541053T1 AT 06022167 T AT06022167 T AT 06022167T AT 06022167 T AT06022167 T AT 06022167T AT E541053 T1 ATE541053 T1 AT E541053T1
Authority
AT
Austria
Prior art keywords
lung cancer
small cell
cell lung
methods
compositions
Prior art date
Application number
AT06022167T
Other languages
English (en)
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE541053T1 publication Critical patent/ATE541053T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
AT06022167T 2002-09-30 2003-09-22 Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs ATE541053T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41467302P 2002-09-30 2002-09-30
US45137403P 2003-02-28 2003-02-28
US46610003P 2003-04-28 2003-04-28

Publications (1)

Publication Number Publication Date
ATE541053T1 true ATE541053T1 (de) 2012-01-15

Family

ID=32074369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06022167T ATE541053T1 (de) 2002-09-30 2003-09-22 Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs

Country Status (8)

Country Link
EP (30) EP2270224A3 (de)
JP (4) JP4425141B2 (de)
KR (2) KR101075158B1 (de)
AT (1) ATE541053T1 (de)
AU (1) AU2003272088A1 (de)
CA (1) CA2500151A1 (de)
TW (1) TW200413725A (de)
WO (1) WO2004031413A2 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300469A (en) * 1992-12-08 1994-04-05 Engelhard Corporation Composition for passivating vanadium in catalytic cracking and preparation thereof
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
EP1576131A4 (de) * 2002-08-15 2008-08-13 Genzyme Corp Expressionsmuster in hirnendothelzellen
CA2512337A1 (en) * 2003-01-03 2004-07-29 Gencia Corporation Sirna mediated post-transcriptional gene silencing of genes involved in alopecia
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP2007530921A (ja) * 2004-03-24 2007-11-01 オンコセラピー・サイエンス株式会社 非小細胞肺癌に対する腫瘍マーカーおよび治療標的としてのａｄａｍ８
JP4658936B2 (ja) * 2004-03-24 2011-03-23 オンコセラピー・サイエンス株式会社 肺癌を治療するための組成物および方法
ATE483979T1 (de) * 2004-08-10 2010-10-15 Oncotherapy Science Inc Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa
DE602005025231D1 (de) * 2004-08-10 2011-01-20 Oncotherapy Science Inc Gene und polypeptide in verbindung mit brustkrebserkrankungen
DE602005023329D1 (de) * 2004-09-24 2010-10-14 Oncotherapy Science Inc VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
EP1812796B1 (de) * 2004-10-19 2009-12-09 Oncotherapy Science, Inc. Pkp3-onkogen als prognostischer indikator für lungenadenokarzinom
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
JP2008523816A (ja) * 2004-12-15 2008-07-10 ベス イスラエル ディーコネス メディカル センター 妊娠合併症の診断および処置に有用な核酸およびポリペプチド
EP2295601A1 (de) 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Verfahren zur Diagnose von Blasenkrebs
EP1853703B1 (de) * 2005-02-25 2011-04-13 Oncotherapy Science, Inc. Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert
EP1854473A1 (de) * 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Mittel zur prävention/therapie von krebs
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
JP2008539693A (ja) * 2005-05-12 2008-11-20 オンコセラピー・サイエンス株式会社 抗ｄｓｃ２抗体のエフェクター機能を用いて細胞を障害する方法
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
KR100759288B1 (ko) * 2005-11-14 2007-09-17 가톨릭대학교 산학협력단 비교유전자보합법을 이용한 폐암 및 폐암의 하부유형 진단방법
US8138167B2 (en) 2006-02-10 2012-03-20 Oncotherapy Science, Inc. Methods for treating lung cancers
EP2018440A1 (de) * 2006-04-20 2009-01-28 Oncotherapy Science, Inc. Nmu-ghsr1b/ntsr1-onkogen-signalweg als therapeutisches ziel bei lungenkrebs
WO2008014951A1 (en) * 2006-08-01 2008-02-07 Roche Diagnostics Gmbh Use of nnmt as a marker for lung cancer
WO2008020653A1 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Use of holliday junction-recognizing protein related to cancer
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
EP2059610A1 (de) * 2006-08-18 2009-05-20 Oncotherapy Science, Inc. Imp-1-onkogen als therapieziel und prognoseindikator für lungenkrebs
EP2061900A2 (de) 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostische marker und therapeutische ziele bei lungenkrebs
US20080145313A1 (en) * 2006-08-30 2008-06-19 Genesis Research & Development Corporation Limited Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders
BRPI0717651A2 (pt) 2006-10-17 2013-12-24 Oncotherapy Science Inc Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1
TW200831673A (en) 2006-12-13 2008-08-01 Oncotherapy Science Inc TTK as tumor marker and therapeutic target for lung cancer
KR100846354B1 (ko) * 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
WO2008120812A1 (en) * 2007-03-30 2008-10-09 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
WO2008151110A2 (en) * 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
WO2009016691A1 (en) * 2007-07-30 2009-02-05 Oncotherapy Science, Inc. Cancer associated gene ly6k
JP5555952B2 (ja) 2007-08-20 2014-07-23 オンコセラピー・サイエンス株式会社 Ｆｏｘｍ１ペプチドおよびこれを含む薬剤
MX2010002018A (es) 2007-08-20 2010-05-27 Oncotherapy Science Inc Peptido de cdh3 y agente medicinal que comprende al mismo.
MX2010002001A (es) * 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido cdca1 y agente farmaceutico que comprende elmismo.
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
WO2009063970A1 (ja) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. 抗gpr49抗体を用いる癌の診断および治療
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
JP5593560B2 (ja) 2008-06-30 2014-09-24 オンコセラピー・サイエンス株式会社 放射性同位体標識で標識された抗ｃｄｈ３抗体およびその使用
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010023837A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Breast cancer related gene rqcd1
WO2010023856A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Pancreatic cancer related gene ttll4
BRPI0917350A2 (pt) * 2008-08-28 2015-08-11 Oncotherapy Science Inc Oip5 como um gene alvo para terapia e diagnose de câncer
KR101064561B1 (ko) * 2008-09-24 2011-09-14 고려대학교 산학협력단 폐선암 수술 후 초기 재발 예측용 바이오마커
WO2010067487A1 (en) * 2008-12-12 2010-06-17 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
ES2703714T3 (es) 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
WO2011027807A1 (ja) * 2009-09-03 2011-03-10 東レ株式会社 免疫誘導剤
JP5728718B2 (ja) 2009-12-28 2015-06-03 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体およびその使用
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
KR101872284B1 (ko) 2010-03-11 2018-06-28 온코세라피 사이언스 가부시키가이샤 Ｈｊｕｒｐ 펩티드 및 이를 포함한 백신
WO2011129427A1 (ja) * 2010-04-16 2011-10-20 第一三共株式会社 癌の診断剤および治療剤
SG187633A1 (en) 2010-07-30 2013-03-28 Oncotherapy Science Inc Quinoline derivatives and melk inhibitors containing the same
WO2012028899A1 (en) * 2010-09-02 2012-03-08 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment and the diagnosis of cancer
EP2702411A4 (de) * 2011-04-29 2015-07-22 Cancer Prevention & Cure Ltd Verfahren zur identifikation und diagnose von lungenkrankheiten mithilfe von klassifizierungssystemen und kits dafür
WO2012153492A1 (en) * 2011-05-06 2012-11-15 Oncotherapy Science, Inc. Nptx2 as tumor marker and therapeutic target for cancer
WO2012157239A1 (en) * 2011-05-16 2012-11-22 Oncotherapy Science, Inc. Chodl as tumor marker and therapeutic target for cancer
JP5564730B2 (ja) 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
CN103987861A (zh) 2011-10-14 2014-08-13 加州大学评议会 皮肤鳞状细胞癌和假性上皮瘤样增生的基于多重pcr的测试及其区分方法
DK2753329T3 (en) 2012-01-19 2017-10-23 Onco Therapy Science Inc 1,5-NAPHTHYRIDINE INGREDIENTS AS MILK INHIBITORS
KR101308924B1 (ko) * 2012-02-21 2013-09-23 차의과학대학교 산학협력단 신규한 ｍｉＲＮＡ ｈｃ－ｓｍＲ－Ｓ２－５ 및 이의 용도
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
JP6255593B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン
US9644010B2 (en) 2012-07-10 2017-05-09 Oncotherapy Science, Inc. LY6K epitope peptides for TH1 cells and vaccines containing the same
GB201213229D0 (en) * 2012-07-25 2012-09-05 Isis Innovation Assay
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR101447901B1 (ko) * 2013-04-16 2014-10-16 한양대학교 산학협력단 지방세포 표적 비바이러스성 유전자 전달체
TWI627182B (zh) 2013-05-24 2018-06-21 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗
JP2017516501A (ja) 2014-05-30 2017-06-22 ジーンセントリック ダイアグノスティクス， インコーポレイテッド 肺がんのタイピング法
SG10201900835XA (en) 2014-08-04 2019-03-28 Oncotherapy Science Inc Urlc10-derived peptide and vaccine containing same
EP3981416B1 (de) 2014-08-04 2024-03-20 OncoTherapy Science, Inc. Koc1-abgeleitetes peptid und impfstoff damit
WO2016121715A1 (ja) * 2015-01-26 2016-08-04 国立大学法人名古屋大学 肺がん患者の予後を評価するための情報を提供する方法、肺がん患者の予後予測方法、内部標準、抗体、肺がん患者の予後予測装置、予後予測装置のプログラム及び記録媒体
US20190203296A1 (en) * 2015-04-14 2019-07-04 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
US20190185851A1 (en) * 2015-09-09 2019-06-20 Theoria Science Inc. Exosome secretion inhibitor
BR112018005581A2 (pt) 2015-10-08 2018-10-16 Oncotherapy Science, Inc. peptídeo derivado de foxm1 e vacina incluindo o mesmo
US10793599B2 (en) 2015-10-08 2020-10-06 Oncotherapy Science, Inc. MPHOSPH1-derived peptide, and vaccine including same
WO2021016946A1 (zh) 2019-07-31 2021-02-04 京东方科技集团股份有限公司 显示基板及其制备方法、显示面板、显示装置
JP7241352B2 (ja) 2016-05-17 2023-03-17 ジーンセントリック セラピューティクス， インコーポレイテッド 肺扁平上皮癌のサブタイピングのための方法
CA3024747A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
SG10202100683RA (en) 2016-08-31 2021-03-30 Oncotherapy Science Inc Monoclonal antibody against melk and utilization thereof
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
NL2020004B1 (en) 2016-12-09 2018-07-02 Ary Flohil Jacob Treatment of diffuse intrinsic pontine glioma
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
CN110709936A (zh) 2017-04-04 2020-01-17 肺癌蛋白质组学有限责任公司 用于早期肺癌预后的基于血浆的蛋白质概况分析
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
KR102540416B1 (ko) * 2021-04-09 2023-06-12 주식회사 애티스랩 암 진단용 조성물, 키트, 및 이를 이용한 암 진단 방법
KR102732170B1 (ko) 2021-05-20 2024-11-19 한국식품연구원 구강미생물 정보를 이용한 폐암의 조기진단 및 위험성 예측 방법 또는 이를 위한 조성물
CN113925877B (zh) * 2021-10-28 2022-06-07 青岛西凯生物技术有限公司 基因增强型免疫细胞在肺癌中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (de) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Verfahren zur Herstellung eines Human-Human-Hybridoms
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
GB9114005D0 (en) 1991-06-28 1991-08-14 Automotive Prod Plc A clutch control system
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5403494A (en) 1993-07-15 1995-04-04 The Lawrence Paper Company Method of recovery of single color printing ink wastes
EP0822830B1 (de) 1995-04-27 2008-04-02 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2002519000A (ja) * 1998-01-28 2002-07-02 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物ｉｉ
AU4187499A (en) * 1998-05-14 1999-11-29 Chiron Corporation Human genes and gene expression products v
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
EP1130094A3 (de) * 1999-07-08 2001-11-21 Helix Research Institute Primer zur Synthese von vollständigen cDNA Klonen und ihre Verwendung
ATE420175T1 (de) * 1999-08-12 2009-01-15 Agensys Inc C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
EP1572987A4 (de) * 2000-02-03 2005-11-30 Nuvelo Inc Neuartige nukleinsäure und polypeptide
JP2003528630A (ja) * 2000-03-28 2003-09-30 カイロン コーポレイション ヒト遺伝子および発現産物
US20020119156A1 (en) * 2000-03-29 2002-08-29 Sei-Yu Chen Compositions and methods of diagnosing, monitoring, staging, imaging and treating lung cancer
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004509612A (ja) * 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
EP1343886A2 (de) * 2000-07-11 2003-09-17 Corixa Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von lungenkrebs
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
ATE553112T1 (de) * 2001-02-21 2012-04-15 Novartis Vaccines & Diagnostic Ttk in der diagnose und als therapeutisches target bei krebs
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
JP4658936B2 (ja) * 2004-03-24 2011-03-23 オンコセラピー・サイエンス株式会社 肺癌を治療するための組成物および方法
EP1853703B1 (de) * 2005-02-25 2011-04-13 Oncotherapy Science, Inc. Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert
EP2061900A2 (de) * 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostische marker und therapeutische ziele bei lungenkrebs
TW200920406A (en) * 2007-08-24 2009-05-16 Oncotherapy Science Inc EBI3, DLX5, NPTX1 and CDKN3 for target genes of lung cancer therapy and diagnosis

Also Published As

Publication number Publication date
JP4921522B2 (ja) 2012-04-25
EP2270502A3 (de) 2011-01-26
EP2270215A2 (de) 2011-01-05
AU2003272088A1 (en) 2004-04-23
EP2270499A1 (de) 2011-01-05
EP2270210A2 (de) 2011-01-05
EP2270501A2 (de) 2011-01-05
CA2500151A1 (en) 2004-04-15
WO2004031413A3 (en) 2005-02-24
EP2270220A3 (de) 2011-09-28
EP2270501A3 (de) 2011-01-19
EP2278028A1 (de) 2011-01-26
JP2012125247A (ja) 2012-07-05
EP2270221A3 (de) 2011-09-28
EP2270498A2 (de) 2011-01-05
EP2264457A1 (de) 2010-12-22
AU2003272088A8 (en) 2004-04-23
EP2264186A1 (de) 2010-12-22
KR20050074468A (ko) 2005-07-18
EP2270213A2 (de) 2011-01-05
WO2004031413A2 (en) 2004-04-15
EP2270222A2 (de) 2011-01-05
EP2270500A1 (de) 2011-01-05
EP1743947A3 (de) 2007-05-23
EP2270216A3 (de) 2011-07-20
EP2270220A2 (de) 2011-01-05
EP2270502A2 (de) 2011-01-05
EP2270224A3 (de) 2011-10-05
EP2270219A3 (de) 2011-07-27
JP2010042016A (ja) 2010-02-25
EP2270225A3 (de) 2011-10-05
JP2009240313A (ja) 2009-10-22
EP1743947A2 (de) 2007-01-17
EP2270211A2 (de) 2011-01-05
EP2264185A1 (de) 2010-12-22
EP2270498A3 (de) 2011-02-02
JP2006500949A (ja) 2006-01-12
KR101075158B1 (ko) 2011-10-19
EP2270224A2 (de) 2011-01-05
EP2270210A3 (de) 2011-06-22
EP2270219A2 (de) 2011-01-05
EP2270215A3 (de) 2011-07-20
EP2264190A1 (de) 2010-12-22
KR20110020953A (ko) 2011-03-03
EP2270212A3 (de) 2011-06-29
EP2270503A2 (de) 2011-01-05
JP4425141B2 (ja) 2010-03-03
EP2270211A3 (de) 2011-06-22
EP2270221A2 (de) 2011-01-05
EP2270223A2 (de) 2011-01-05
EP1551998A2 (de) 2005-07-13
EP1743947B1 (de) 2012-01-11
EP2264187A1 (de) 2010-12-22
EP2270503A3 (de) 2011-01-19
EP2270218A2 (de) 2011-01-05
TW200413725A (en) 2004-08-01
EP2270214A3 (de) 2011-07-20
EP2270214A2 (de) 2011-01-05
WO2004031413A9 (en) 2005-08-04
EP2270213A3 (de) 2011-06-29
EP2270216A2 (de) 2011-01-05
EP2270212A2 (de) 2011-01-05
EP2270217A2 (de) 2011-01-05
EP2270225A2 (de) 2011-01-05
EP2270217A3 (de) 2011-07-27

Similar Documents

Publication Publication Date Title
ATE541053T1 (de) Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
ATE511503T1 (de) Aryl- und heteroarylharnstoff-chk1-inhibitoren zur verwendung als radiosensibilisatoren und chemosensibilisatoren
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
DE602004015064D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
ATE522623T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60020591D1 (de) Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
DE502004009491D1 (de) Thiaepothilone zur behandlung von krebserkrankungen
ATE411313T1 (de) Neue makrocyclen zur behandlung von krebserkrankungen
DE69735636D1 (de) Verfahren zur bestimmung des malignen zellezustands und verfahren zur behandlung